🟡 Preliminary Evidence
Margaret Hvatum’s case illustrates a critical failure in the prior-authorization process—a gatekeeping mechanism that U.S. insurers use to control medication costs but which increasingly delays or blocks access to clinically necessary treatments. After her insurer, Humana Medicare Advantage, delayed approval of an immune-boosting medication she depends on, Hvatum was hospitalized, raising questions about whether prior-authorization reforms promised by the insurance industry are being implemented in practice.
Key takeaways
- Prior-authorization delays led to hospitalization of a Medicare beneficiary who could not access an essential immune-boosting medication
- The insurance industry has publicly committed to reducing approval times, yet delays persist in practice
- Cases like Hvatum’s underscore the gap between industry pledges and real-world implementation of prior-authorization reform
The Prior-Authorization Problem: Delays in Access to Necessary Medications
Documented case outcomes and timeline delays in prior-authorization processes for Medicare Advantage beneficiaries, 2026
Source: KFF Health News, June 2026 | Georgian Medical Journal News
What Prior Authorization Does—and What Went Wrong
Prior authorization is a requirement that insurers approve medical treatments before patients receive them, ostensibly to prevent unnecessary or costly procedures. According to KFF Health News, Hvatum’s case involved an immune-boosting medication that her physician deemed clinically necessary. Despite this clinical indication, her insurer, Humana Medicare Advantage, delayed approval, leaving her without access to the medication during a critical period.
The delays forced Hvatum into the hospital—a documented outcome that raises fundamental questions about whether prior-authorization procedures protect patients or harm them. Quality and safety advocates have long noted that administrative delays can escalate clinical conditions, turning preventable complications into acute hospitalizations.
Industry Pledges Versus Real-World Practice
The insurance industry has publicly committed to speeding up prior-authorization approvals. However, cases like Hvatum’s suggest that these pledges have not translated into consistent practice changes across all insurers and treatment types. According to documentation by KFF Health News, Humana’s delay in this case did not reflect the efficiency improvements the industry has promised.
The gap between commitment and implementation reflects a systemic challenge: prior-authorization systems remain opaque, inconsistent across insurers, and often burden clinicians with administrative tasks that delay clinical decision-making. Hvatum’s experience is not isolated—it is symptomatic of a broader clinical practice problem that affects medication access across the U.S. healthcare system.
Implications for Medicare Beneficiaries
For Medicare Advantage beneficiaries like Hvatum, prior authorization creates a significant risk: access to necessary medications depends not on clinical need alone, but on an insurer’s administrative timeline and approval criteria. This introduces an additional layer of uncertainty and potential harm, particularly for patients with complex or time-sensitive conditions requiring immune system support or other maintenance therapies.
The American medical system relies on clinicians to make treatment decisions based on evidence and patient need. When insurers insert administrative delays between clinical recommendation and medication access, patient outcomes can deteriorate—as Hvatum’s hospitalization demonstrates. This raises questions about whether prior authorization, as currently implemented, serves its stated purpose of protecting patients from unnecessary care, or whether it instead creates barriers to necessary care.
A Medicare beneficiary requiring an immune-boosting medication was hospitalized after her insurer delayed prior-authorization approval, despite clear clinical indication for the drug.
— KFF Health News, June 2026
What this means
Frequently asked questions
What is prior authorization, and why do insurers use it?
Prior authorization is a requirement that insurers approve a medication or procedure before a patient receives it. Insurers argue it reduces unnecessary care and costs. However, critics note that approval delays can harm patients with time-sensitive conditions, as illustrated by Hvatum’s case. Research on its effectiveness remains mixed, with health policy experts increasingly questioning whether its benefits outweigh the administrative burden and access delays it creates.
Can patients or doctors appeal a denied or delayed prior authorization?
Yes. Under Medicare Advantage rules, patients and their clinicians can appeal denials and request expedited review for urgent cases. However, the appeal process itself can take time, and success depends on the insurer’s criteria and documentation. In Hvatum’s case, the initial delay occurred during the standard review process—suggesting that even appeal mechanisms may not prevent all access delays.
Are all Medicare Advantage plans equally slow at prior authorization?
No. Prior-authorization approval times vary significantly among insurers. Humana, UnitedHealthcare, Cigna, and other major Medicare Advantage operators maintain different criteria and timelines. According to KFF Health News, Hvatum’s experience with Humana reflects a documented problem across the industry, but individual cases vary. Patients should ask their plan’s customer service about typical approval times for their specific medications.
Hvatum’s hospitalization underscores a critical reality: insurance company administrative processes directly affect patient health outcomes. As the U.S. healthcare system debates prior-authorization reform, cases like hers must inform policy. The insurance industry’s public commitments to faster approvals must be paired with transparent, enforceable timelines and independent oversight—otherwise, administrative delays will continue to transform preventable complications into costly, avoidable hospitalizations. Global health and quality advocates increasingly recognize that healthcare access barriers, even when administratively framed, are ultimately public health failures.
Source: She Struggled To Get a Lifesaving Drug Even After Insurers Vowed To Help, KFF Health News, June 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
